Browsing: moves

Evelyne Bischof on why credible training of doctors in healthy longevity is one of the most important health innovations of…

FDA greenlights early-stage trial of VectorY’s first-in-class therapy targeting the core biology driving most ALS cases. Netherlands-based biotech VectorY Therapeutics…

Early biomarker engagement and clean safety data position VNA-318 as a potential new entrant in longevity-focused neurotherapeutics. Vandria has reported…

Credit: Pixelbizz/Getty Images Big pharma Bristol Myers Squibb (BMS) has agreed to acquire RNA biotech Orbital Therapeutics for $1.5 Billion.…

Longevity biotech seeks to broaden its therapeutic capabilities with cellular reprogramming and delivery technologies. Longevity-focused biotech Klotho Neurosciences revealed it…